Pacific Edge Investor Update: Q1 FY23 Test Volumes Rise 32%

Wednesday 20th July 2022

DUNEDIN, New Zealand -- Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces continuing strong growth in volumes through its laboratories of its market-leading genomic biomarker Cxbladder tests.

In the three months to the end of June 2022 Pacific Edge processed 7,055 tests up 13% on the 6,242 tests in the three months to the end of March 2022. The June 2022 figure also represents a 32% increase on the 5,356 tests processed in the same quarter of the prior financial year.

The throughput figures are disclosed in the company’s June 2022 quarterly Investor Update (attached) alongside historical quarterly test volumes starting from the first quarter of the 2021 financial year. These figures show the company has delivered a compound annual growth in test volumes since 2021 of 54%.

Pacific Edge intends to report these figures to the NZX and ASX as soon as practicable after the end of each quarter, while continuing to deliver a comprehensive data set with its full and half year results in May and November of each year.

Further detail on test volumes is covered in the attached Investor Update.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

Dr Peter Meintjes

Chief Executive

Pacific Edge

P: +64 22 032 1263

Coran Lill

The Project

P: +64 27 342 3836

OVERVIEW www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder: www.cxbladder.com

Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy.

Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.

Pacific Edge Investor Update: Q1 FY23 Test Volumes Rise 32%

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Pacific Edge Investor Update: Q1 FY23 Test Volumes Rise 32%

Comments from our readers

Add your comment:

Related News: